Skip to main content
AAN.com

Abstract

Objective:

To determine whether the ratio single chain (sc)/(sc + 2 chain [tc]) recombinant tissue plasminogen activator (rtPA) influences outcomes in patients with cerebral ischemia.

Methods:

We prospectively included consecutive patients treated with IV rtPA for cerebral ischemia in 13 stroke centers and determined the sc/(sc + tc) ratio in the treatment administered to each patient. We evaluated the outcome with the modified Rankin Scale (mRS) at 3 months (prespecified analysis) and occurrence of epileptic seizures (post hoc analysis). We registered Outcome of Patients Treated by IV Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA (OPHELIE) under ClinicalTrials.gov identifier no. NCT01614080.

Results:

We recruited 1,004 patients (515 men, median age 75 years, median onset-to-needle time 170 minutes, median NIH Stroke Scale score 10). We found no statistical association between sc/(sc + tc) ratios and handicap (mRS > 1), dependency (mRS > 2), or death at 3 months. Patients with symptomatic intracerebral hemorrhages had lower ratios (median 69% vs 72%, adjusted p = 0.003). The sc/(sc + tc) rtPA ratio did not differ between patients with and without seizures, but patients with early seizures were more likely to have received a sc/(sc + tc) rtPA ratio >80.5% (odds ratio 3.61; 95% confidence interval 1.26–10.34).

Conclusions:

The sc/(sc + tc) rtPA ratio does not influence outcomes in patients with cerebral ischemia. The capacity of rtPA to modulate NMDA receptor signaling might be associated with early seizures, but we observed this effect only in patients with a ratio of sc/(sc + tc) rtPA >80.5% in a post hoc analysis.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (co-investigators_appendix_220716.doc)
File (e-tables.pdf)

REFERENCES

1.
Docagne F, Parcq J, Lijnen R, Ali C, Vivien D. Understanding the functions of endogenous and exogenous tissue-type plasminogen activator during stroke. Stroke 2015;46:314–320.
2.
Parcq J, Bertrand T, Montagne A, et al. Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ 2012;19:1983–1991.
3.
Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009;32:48–55.
4.
Bertrand T, Lesept F, Chevilley A, et al. Conformations of tissue plasminogen activator (tPA) orchestrate neuronal survival by a crosstalk between EGFR and NMDAR. Cell Death Dis 2015;6:e1924.
5.
Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–1587.
6.
Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
7.
Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929–1935.
8.
The European Stroke Organisation (ESO) Executive Committee; ESO Writing Commitee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457–507.
9.
Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245–1251.
10.
Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training: NINDS tPA Stroke Study Group. Stroke 1994;25:2220–2226.
11.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–607.
12.
Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
13.
Bendel RB, Afifi AA. Comparison of stopping rules in forward regression. J Am Stat Assoc 1977;72:46–53.
14.
Glantz SA, Slinker BK. Primer of Applied Regression and Analysis of Variance. New York: McGraw Hill; 1990.
15.
Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275–282.
16.
Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study (CASES). CMAJ 2005;172:1307–1312.
17.
Nakagawara J, Minematsu K, Okada Y, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010;41:1984–1989.
18.
Orset C, Macrez R, Young AR, et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 2007;38:2771–2778.
19.
Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost 2007;5:804–811.
20.
Alvarez V, Rossetti AO, Papavasileiou V, Michel P. Acute seizures in acute ischemic stroke: does thrombolysis have a role to play? J Neurol 2013;260:55–61.
21.
Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993;361:453–457.
22.
Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340–344.
23.
Yepes M, Sandkvist M, Coleman TA, et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 2002;109:1571–1578.
24.
Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci USA 2005;102:443–448.
25.
Iyer AM, Zurolo E, Boer K, et al. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies. Neuroscience 2010;167:929–945.
26.
Peeling J, Sutherland G. 1H magnetic resonance spectroscopy of extracts of human epileptic neocortex and hippocampus. Neurology 1993;43:589–594.
27.
Chevilley A, Lesept F, Lenoir S, Ali C, Parcq J, Vivien D. Impacts of tissue-type plasminogen activator (tPA) on neuronal survival. Front Cell Neurosci 2015;9:415.
28.
Lamy C, Domigo V, Semah F, et al. Early and late seizures after cryptogenic ischemic stroke in young adults. Neurology 2003;60:400–404.
29.
Beghi E, D'Alessandro R, Beretta S, et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology 2011;77:1785–1793.
30.
Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004;35:1769–1775.
31.
Berges S, Moulin T, Berger E, et al. Seizures and epilepsy following strokes: recurrence factors. Eur Neurol 2000;43:3–8.
32.
Rumbach L, Sablot D, Berger E, Tatu L, Vuillier F, Moulin T. Status epilepticus in stroke: report on a hospital-based stroke cohort. Neurology 2000;54:350–354.
33.
Cordonnier C, Hénon H, Derambure P, Pasquier F, Leys D. Early epileptic seizures after stroke are associated with increased risk of new-onset dementia. J Neurol Neurosurg Psychiatry 2007;78:514–516.
34.
Cordonnier C, Henon H, Derambure P, Pasquier F, Leys D. Influence of pre-existing dementia on the risk of post-stroke epileptic seizures. J Neurol Neurosurg Psychiatry 2005;76:1649–1653.

Information & Authors

Information

Published In

Neurology®
Volume 87Number 23December 6, 2016
Pages: 2416-2426
PubMed: 27815401

Publication History

Received: March 15, 2016
Accepted: August 30, 2016
Published online: November 4, 2016
Published in print: December 6, 2016

Permissions

Request permissions for this article.

Disclosure

D. Leys is an investigator of ECASS 4, an investigator-driven trial. Y. Hommet reports no disclosures relevant to the manuscript. C. Jacquet is an investigator of ECASS 4, an investigator-driven trial. S. Moulin is an investigator of ECASS 4, an investigator-driven trial. I. Sibon reports no disclosures relevant to the manuscript. J. Mas is an investigator of ECASS 4, an investigator-driven trial, and has participated in symposia organized by Boehringer-Ingelheim. T. Moulin, M. Giroud, and S. Sagnier report no disclosures relevant to the manuscript. C. Cordonnier is an investigator of ECASS 4, an investigator-driven trial. E. Medeiros de Bustos reports no disclosures relevant to the manuscript. G. Turc is an investigator of ECASS 4, an investigator-driven trial. T. Ronzière, Y. Bejot, O. Detante, T. Ouk, A. Mendyk, P. Favrole, M. Zuber, A. Triquenot-Bagan, and O. Ozkul-Wermester report no disclosures relevant to the manuscript. F. Macian Montoro has participated in trials and symposia organized by Boehringer-Ingelheim. C. Lamy, A. Faivre, L. Lebouvier, C. Potey, and M. Poli report no disclosures relevant to the manuscript. H. Hénon is an investigator of ECASS 4, an investigator-driven trial. P. Renou reports no disclosures relevant to the manuscript. N. Dequatre-Ponchelle is an investigator of ECASS 4, an investigator-driven trial. M. Bodenant is an investigator of ECASS 4, an investigator-driven trial. S. Debruxelles reports no disclosures relevant to the manuscript. C. Rossi is an investigator of ECASS 4, an investigator-driven trial. R. Bordet and D. Vivien report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Study Funding

This study was supported by grants from INSERM (French National Institute for Health and Medical Research, INSERM UMR-S U1171 and U919), University of Lille, Lille University Hospital, Adrinord, University Caen-Normandie, FP7 Eranet-NEURON 3-275-006, Team FRM N°DEQ20140329555, Ministry of Health (Strokavenir Network, PHRC grant). Alicante made the e-CRF available.

Authors

Affiliations & Disclosures

Didier Leys, MD, PhD, FESO
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
1) Scientific advisory boards for Pharmaceutical or device companies (No direct honoraria received by myself : were paid to the research institution): BMS, Boeringher- Ingelheim, Bayer, Astrazeneca, Nestl?, 2) Member of DSMBs for institutional trials (no honoraria): INCH (Germany), TARDIS (UK), and TO-ACT (the Netherlands)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
European Stroke Journal. Vice-editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Symposia organised by Boeringher Ingelheim Bayer BMS (honoraria paid to the research institution)
Other Activities:
1.
Drug trials with Sanofi Aventis, Astrazeneca, Boeringher- Ingelheim, Brainsgate, Photothera, Lundbeck, GSK, Pierre Fabre. (Honoraria paid to Adrinord or to the hospital)
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Honoraria paid to the research institution (Adrinord) - Boeringher ingelheim (advisory boards in France and Europe)
Research Support, Government Entities:
1.
PHRC grant EU grant
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Yannick Hommet, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Clémence Jacquet, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) AstraZeneca, funding for travel to conference (ESOC mai 2016)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
(1) Drug trial with Boeringher-Ingelheim (no honoraria)
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Solène Moulin, MD, MSc
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
Dr. Sol?ne Moulin is investigator of ECASS4 an investigator-driven trial
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Igor Sibon, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jean-Louis Mas, MD, PhD, FESO, FEAN
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
Boehringer-Ingelheim
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Boehringer-Ingelheim
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) French Ministry of Health, 1 grant, coordination of a randomized clinical trial, ongoing (2) INSERM Institut National Scientifique Et de la Recherche Medicale, financing a Stroke Research Unit, ongoing
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Thierry Moulin, MD, PhD, FESO, FEAN
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Maurice Giroud, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sharmila Sagnier, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Charlotte Cordonnier, MD, PhD, FESO
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
investigator in ECASS-4, an investigation driven trial
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Elisabeth Medeiros de Bustos, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Guillaume Turc, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Thomas Ronzière, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Yannick Bejot, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
(1) AstraZeneca: scientific advisory board (2) Pfizer: scientific advisory board (3) Daiichi-Sankyo: scientific advisory board (4) Covidiem : scientific advisory board
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) MSD: speaker honoraria (2) Bayer: speaker honoraria
Editorial Boards:
1.
(1) Stroke: Editorial board since 2015, no financial compensation
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Olivier Detante, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Thavarak Ouk, Pharm D, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Anne-Marie Mendyk, RN
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Pascal Favrole, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Mathieu Zuber, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
Bayer Boehringer Ingelheim
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Bayer, honoraria Boehringer Ingelheim, honoraria
Editorial Boards:
1.
Revue Neurologique (Paris), editorial advisory board member
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Aude Triquenot-Bagan, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ozlem Ozkul-Wermester, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Francisco Macian Montoro, MD, MSc
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
participated in trials and symposia organized by Boehringer-Ingelheim
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Boehringer-Ingelheim, local expert witness for anticoagulant treatements
Chantal Lamy, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Anthony Faivre, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Laurent Lebouvier, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Camille Potey, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Mathilde Poli, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Hilde Hénon, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
co-investigator ECASS-4
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Pauline Renou, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Nelly Dequatre-Ponchelle, MD, MSc
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marie Bodenant, MD, MSc
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
investigator of ECASS 4 an investigator-driven trial
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sabrina Debruxelles, MD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Costanza Rossi, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Régis Bordet, MD, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Denis Vivien, PhD
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
W02013/034710A1. Mutated tissue plasminogen activators and uses thereof. (EP11306119.6), 09/2012)
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultancies for pharma: PAION (Aachen, Germany) Lundbeck (Copenhaguen, Sweden)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
4 ANR (Agence Nationale de la Recherche) contracts from 2006 : 1 Neurosciences, 1 Emergence, 2 BiotecS for a total of 1000 kE; 3 programmes ?mergence of the regional council of lower-Normandy for a total of 900 kE since 2005, 2 junior project of the regional council of lower-Normandy (2012-2015): 400 kE.
Research Support, Academic Entities:
1.
INSERM Avenir subvention (2005-2008): 500 kE; FP7 ?
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
For the OPHELIE investigators and the STROKAVENIR network
From Degenerative & Vascular Cognitive Disorders (D.L., C.J., S.M., C.C., T.O., A.-M.M., C.P., H.H., N.D.-P., M.B., C.R., R.B.), Department of Neurology, INSERM U 1171, CHU Lille, Universite Lille; Strokavenir Network (D.L., Y.H., C.J., S.M., I.S., J.-L.M., T.M., M.G., S.S., C.C., E.M.d.B., G.T., T.R., Y.B., O.D., T.O., A.-M.M., P.F., M.Z., A.T.-B., O.O.-W., F.M.M., C.L., A.F., L.L., C.P., M.P., H.H., P.R., N.D.-P., M.B., S.D., C.R., R.B., D.V.), Lille; Inserm UMR-S 919 (Y.H., L.L., D.V.), University Caen-Normandie, GIP Cyceron, Caen; Bordeaux University Hospital (I.S., S.S., M.P., P.R., S.D.), University of Bordeaux; INSERM UMR S894 (J.-L.M., G.T.), Sainte-Anne Hospital, DHU NeuroVasc, Sorbonne Paris Cité, University Paris Descartes; Besançon University Hospital (T.M., E.M.d.B.), University of Franche-Comté; Dijon Stroke Registry (INSERM and INVS) (M.G., Y.B.), Dijon University Hospital, University of Burgundi; University of Rennes (T.R.); University Grenoble Alpes (O.D.); University Hospital Paris Tenon (P.F.); Sorbonne Paris Citéitbonne, University Hospital Paris St Joseph, University Paris Descartes; Rouen University Hospital (A.T.-B., O.O.-W.); University Hospital of Limoges (F.M.M.); Amiens University Hospital (C.L.); and Ste.-Anne Military Teaching Hospital (A.F.), Toulon, France.

Notes

Correspondence to Dr. Leys: [email protected]
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Coinvestigators are listed at Neurology.org

Author Contributions

D. Leys: study design, data analysis, data interpretation, drafting the manuscript. Y. Hommet: conceptualization, analyses, data interpretation, revising the manuscript. C. Jacquet: data analysis, data interpretation, drafting the manuscript. S. Moulin: data interpretation, revising the manuscript. I. Sibon: study design. J.L. Mas: study design. M. Giroud: study design. S. Sagnier: data interpretation, revising the manuscript. C. Cordonnier: data interpretation, revising the manuscript. E. Medeiros de Bustos: data interpretation, revising the manuscript. G. Turc: data interpretation, revising the manuscript. T. Ronzière: data interpretation, revising the manuscript. Y. Bejot: data interpretation, revising the manuscript. O. Detante: data interpretation, revising the manuscript. T. Ouk: feasibility study, data interpretation, revising the manuscript. A.M. Mendyk: feasibility study, study monitoring, data interpretation, revising the manuscript. P. Favrole: data interpretation, revising manuscript. M. Zuber: data interpretation, revising the manuscript. A. Triquenot-Bagan: data interpretation, revising the manuscript. O. Ozkul-Wermester: data interpretation, revising the manuscript. F. Macian Montoro: data interpretation, revising the manuscript. C. Lamy: data interpretation, revising the manuscript. A. Faivre: data interpretation, revising the manuscript. L. Lebouvier: feasibility study, analyses, data interpretation, revising the manuscript. C. Potey: feasibility study, data interpretation, revising the manuscript. M. Poli: data interpretation, revising the manuscript. H. Hénon: data interpretation, revising the manuscript. P. Renou: data interpretation, revising the manuscript. N. Dequatre-Ponchelle: data interpretation, revising the manuscript. M. Bodenant: data interpretation, revising the manuscript. S. Debruxelles: data interpretation, revising the manuscript. C. Rossi: data interpretation, revising the manuscript. R. Bordet: conceptualization, feasibility study, data interpretation, revising the manuscript. D. Vivien: conceptualization, analyses, data analysis, data interpretation, revising the manuscript.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Low-density lipoprotein receptor-related protein-1 (LRP1) in the glial lineage modulates neuronal excitability, Frontiers in Network Physiology, 3, (2023).https://doi.org/10.3389/fnetp.2023.1190240
    Crossref
  2. Impact of drug treatment and drug interactions in post-stroke epilepsy, Pharmacology & Therapeutics, 233, (108030), (2022).https://doi.org/10.1016/j.pharmthera.2021.108030
    Crossref
  3. Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke, Experimental Neurology, 338, (113606), (2021).https://doi.org/10.1016/j.expneurol.2021.113606
    Crossref
  4. Assessment of the incidence and risk factors of early poststroke seizures in Lebanese patients, Brain and Behavior, 11, 11, (2021).https://doi.org/10.1002/brb3.2204
    Crossref
  5. Incidence and Association of Reperfusion Therapies With Poststroke Seizures, Stroke, 51, 9, (2715-2723), (2020).https://doi.org/10.1161/STROKEAHA.119.028899
    Crossref
  6. Cerebral ischaemia with unknown onset: Outcome after recanalization procedure, Revue Neurologique, 176, 1-2, (75-84), (2020).https://doi.org/10.1016/j.neurol.2019.05.004
    Crossref
  7. Early epileptic seizures in ischaemic stroke treated by mechanical thrombectomy: influence of rt-PA, Journal of Neurology, 268, 1, (305-311), (2020).https://doi.org/10.1007/s00415-020-10155-4
    Crossref
  8. Early seizures after ischemic stroke: focus on thrombolysis, CNS Spectrums, 25, 1, (101-113), (2019).https://doi.org/10.1017/S1092852919000804
    Crossref
  9. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond, The Lancet Neurology, 17, 12, (1121-1132), (2018).https://doi.org/10.1016/S1474-4422(18)30323-5
    Crossref
  10. Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke, Journal of Neurology, 265, 5, (1166-1173), (2018).https://doi.org/10.1007/s00415-018-8827-6
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share